Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Combination therapies for CLL: BTKi + BCL2i
IDH1m cells exhibit a higher sensitivity to OxPHOSi and BCL2i due to ...
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL ...
Bcl 2 Protein Pathway
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic ...
BCL-2
Benzilato De Potassio SciELO Brasil Radioligantes Para
国内获批首个BCL-2抑制剂——了解白血病靶向药物维奈托克/维奈克拉(Venetoclax)【海得康海外医疗】
剑指“细胞凋亡”,癌症治疗的福音靶点——BCL-2 - 知乎
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Educational theme│The genomic landscape, biology, epidemiology, and ...
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase ...
【AmBeed解析】探究Bcl-2的作用机制 - 知乎
BCL2 (B-Cell Leukemia/Lymphoma 2)
BCL2 – Center for Molecular Analysis & Research
Bcl-2ファミリー - Wikipedia
Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet ...
Bcl2 Inhibitor Therapy : Mechanisms of Resistance to BCL2 Inhibitor ...
Bcl-2、细胞凋亡以及肿瘤靶向治疗 - 知乎
Time-Limited Innovation for CLL Control: Changing the Treatment Story ...
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia ...
Targeting The Bcl-2 Family In B Cell Lymphoma – ICWT
American Journal of Hematology | Blood Research Journal | Wiley Online ...
Challenge Question
BCL2i-Motif 和 hnRNP LL 之间的转录复合物是控制基因表达的分子开关,可由小分子调节,Journal of the ...
Sequencing single novel agent-based therapy for patients with CLL: A ...
Approved and select investigational targeted therapies in CLL. BCL-2i ...
Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co ...
Schematic diagram showing how chemical inhibitors of Bcl2 proteins ...
Bcl-2 inhibitors (Bcl2i) facilitate Bcl-2-dependent apoptosis in cells ...
Sankey plot of the therapy of the whole cohort, before and after ...
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic ...
Pirtobrutinib for the Treatment of B-Cell Malignancies: Recent ...
Modern Management of Mantle Cell Lymphoma | American Society of ...
Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines ...
BCL2抑制剂最新研究 | Dana-Farber Cancer Institute
Frontiers | Born to be Alive: A Role for the BCL-2 Family in Melanoma ...
Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL ...
Time-Limited Innovation for CLL Control: 1L BTKi -BCL2i Combinations ...
Frontiers | Defining melanoma combination therapies that provide ...
Bcl-2 - Wikipedia
ASH Education: Bcl-2抑制剂-搜狐大视野-搜狐新闻
Invited Review Mechanisms Of Bcl-2 Protein Function – WEVBZ
The BCL-2 Family Reunion: Molecular Cell
BCL-2 family isoforms in apoptosis and cancer - PMC
Bcl-2 – Wikipedia
Bcl-2抑制剂 | Bcl-2 Inhibitor
BTKi及BCL2i经治的后线CLL/SLL临床数据(非头对头对比):BGB-16673和步展现治疗优势 - 2025年08月 - 小牛行研
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes ...
Taking the next step in double refractory disease | OTT | Dove Medical ...
Bcl2 family | PPTX
MEKi and BCL-2i synergize to kill B-ALL cells. (a) Scatter dot plot ...
什么是B细胞淋巴瘤2 (Bcl-2)? - 知乎
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted ...
BTKi for patients with CLL: Class effects, guidelines, and real-world ...
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications ...
Many players in BCL-2 family affairs: Trends in Biochemical Sciences
Frontiers | Targeting the Bcl-2 Family in B Cell Lymphoma
百济神州@JPM2024,创新肿瘤药国内前三 相关阅读:百济神州@JPM2023http:... - 雪球
【Biorbyt科研专题】BCL-2 蛋白家族 - 知乎
Dr. Jacob Soumerai @MassGenBrigham highlights progression on one ...
再不追就晚了|Bcl-2:妥妥的细胞凋亡C位选手 - 每日生物评论
Proposal for approaching Mantle Cell Lymphoma (MCL) at first relapse ...
Drug synergy of the drug combination LSD1i (GSK-LSD1) with JAKi ...
Double identity for proteins of the Bcl-2 family | Nature
BCL2L1 (BCL2-like 1)
BCL-2 Family Composition and Membrane Permeabilization (A) The BCL-2 ...
Clinical Characteristics, Treatment Patterns, and Outcomes of Patients ...
Bcl 2 Pathway
Roles and Regulation of BCL-xL in Hematological Malignancies
Bcl-2基因:作用,結構特性,_中文百科全書
BAI1 | Bcl-2 抑制剂 | 5+篇文献引用 | 国内现货 | Selleck中国
The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond - PMC
Impact of TP53 gene mutations in CLL clinical trials with BCRi and ...
Bcl-2蛋白_百度百科
Full article: Clinical outcomes among patients with chronic lymphocytic ...
Full article: Real-world patterns and sequences of targeted therapy use ...
$NRIX (NP) ~$500M EV, added to DD list (won't get around to for a while ...
2025ASCO 大会国内重点研究总结报告 核心观点⚫ ASCO是肿瘤领域顶级学术会议,多项国内新药数据在大会惊艳亮相。ASCO(美国临床肿瘤 ...
The Bcl-2 Family: Ancient Origins, Conserved Structures, and Divergent ...
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of ...
iwCLL 2025丨梅奥诊所研究:CLL患者单一新型药物序贯治疗——cBTKi→BCL2i与BCL2i→cBTKi对比分析
靶向BCL-2的抑制剂有哪些? - 知乎
Expression Differences in BCL2 Family Members between Uveal and ...
The BCL2 family: from apoptosis mechanisms to new advances in targeted ...
BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting
CLL Safety & Adverse Reactions | Jaypirca® (pirtobrutinib)
BCL-2抑制剂——药研档案
AbbVie Oncology Medical Affairs (@AbbVieUSOncMed) / Posts / X
技术文章
Defining the double refractory patient population. BTKi, Bruton's ...
Full article: Real-world treatment patterns, patient characteristics ...
Society of Hematologic Oncology | Vumedi